- Trials with a EudraCT protocol (120)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
120 result(s) found for: Transient Ischemic Attack.
Displaying page 1 of 6.
EudraCT Number: 2013-001185-41 | Sponsor Protocol Number: POINT | Start Date*: 2013-11-26 | ||||||||||||||||
Sponsor Name:University of California San Francisco Stroke Sciences Group | ||||||||||||||||||
Full Title: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial | ||||||||||||||||||
Medical condition: Transient Ischemic Attack and Minor Stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003959-22 | Sponsor Protocol Number: CV006-004 | Start Date*: 2016-09-06 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS-986141 For the Prevention of Recurrent Brain Infarction in Subjects receiving acet... | ||||||||||||||||||
Medical condition: Recurrent Brain Infarction in Subjects receiving acetylsalicyl acid (ASA) following Acute Ischemic Stroke or Transient Ischemic Attack | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005980-26 | Sponsor Protocol Number: MAAS | Start Date*: 2012-07-04 | ||||||||||||||||||||||||||
Sponsor Name: | ||||||||||||||||||||||||||||
Full Title: Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke - a multicenter, randomized, open-label phase II trial | ||||||||||||||||||||||||||||
Medical condition: Stroke Transient ischemic attack Impaired glucose tolerance | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006971-19 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Aker universitetssykehus | |||||||||||||||||||||||
Full Title: Effect of Aggrenox® / Asasantin® Retard compared with Clopidogrel on Endothelial function as measured by Microalbuminuria, Inflammatory markers CRP, MCP-1, and MMP-9 in Patients with Type 2 Diabet... | |||||||||||||||||||||||
Medical condition: Patients with Type 2 Diabetes Mellitus and a history of TIA or stroke. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005546-23 | Sponsor Protocol Number: IRIS:IND#64,622 | Start Date*: 2009-11-05 |
Sponsor Name:Yale University School of Medicine | ||
Full Title: The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ische... | ||
Medical condition: Insulin resistance in patients who have had a stroke or transient ischaemic attack | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002560-41 | Sponsor Protocol Number: 0611 | Start Date*: 2017-09-21 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Leicester | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker Regimen to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): A Feasibility Trial | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Participants in the trial will have had a transient ischaemic attack (TIA) or an acute ischaemic stroke and will also have hypertension. The trial will investigate the possible treatment of blood p... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003573-32 | Sponsor Protocol Number: 2022/ABM/01/00027 | Start Date*: 2023-12-28 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to evaluate the effect of allopurinol on the risk of cardiovascular events in patients at high and very high cardiovascular risk, including the ... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: hyperuricemia, hypertension, ischemic stroke, intracerebral haemorrhage, TIA, heart failure, peripheral arterial disease, atrial fibrillation, diabetes mellitus | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006749-42 | Sponsor Protocol Number: 31350 | Start Date*: 2009-01-09 | ||||||||||||||||
Sponsor Name:University of Nottingham | ||||||||||||||||||
Full Title: Safety and efficacy of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke or TIA: a randomised controlled trial | ||||||||||||||||||
Medical condition: Ischaemic stroke and TIA (transient ischaemic attack) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001067-27 | Sponsor Protocol Number: 20604 | Start Date*: 2022-11-10 | |||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||
Full Title: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of i... | |||||||||||||||||||||||
Medical condition: Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) HU (Ongoing) ES (Ongoing) AT (Trial now transitioned) FR (Ongoing) IT (Ongoing) BE (Trial now transitioned) GR (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) LV (Ongoing) PT (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003622-29 | Sponsor Protocol Number: BAYe4465/IMPACT12198 | Start Date*: 2007-06-13 | |||||||||||||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||||||||||||
Full Title: The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiov... | |||||||||||||||||||||||||||||||||
Medical condition: Patients at moderate risk of CHD events (10-20% 10-year CHD risk; approximately 30% 10-year risk of CVD events based on the underlying assumption at study start). | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) IE (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000348-14 | Sponsor Protocol Number: NSTATIN | Start Date*: 2014-03-05 |
Sponsor Name:Odense University Hospital, Department of Neurology | ||
Full Title: Statin-treatment and peripheral neuropathy - a randomized clinical trial | ||
Medical condition: Patients with cerebral infarction or transient ischemic attack. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-004224-23 | Sponsor Protocol Number: TSAIMT01 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:University of Glasgow / NHS Greater Glasgow and Clyde | |||||||||||||
Full Title: The effect of allopurinol on carotid ultrasound intima-media thickness and markers of endothelial function in patients with recent stroke - a pilot study. | |||||||||||||
Medical condition: Ischaemic stroke or transient ischaemic attack (TIA) (ICD Classification Code I63.0-9 and G45.0-1). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001675-32 | Sponsor Protocol Number: ARTE | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:IUCPQ | |||||||||||||
Full Title: Aspirin versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation with the Edwards Valve. A Randomized Study (the ARTE trial). | |||||||||||||
Medical condition: Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding at 3-month follow-up. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000620-28 | Sponsor Protocol Number: LPS14245 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:sanofi-aventis groupe | |||||||||||||
Full Title: A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Sever... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) SK (Completed) BE (Completed) IT (Completed) HU (Completed) AT (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) FI (Completed) PL (Completed) GR (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005029-19 | Sponsor Protocol Number: CV010031 | Start Date*: 2020-06-09 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc... | ||||||||||||||||||
Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003895-38 | Sponsor Protocol Number: D5134C00001 | Start Date*: 2014-02-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomised, double-blind, multinational study to prevent major vascular events with Ticagrelor compared to Aspirin(ASA) in patients with acute ischaemic stroke or Transient Ischemic Attack (TIA).... | |||||||||||||
Medical condition: ischaemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) BE (Completed) SE (Completed) DE (Completed) IT (Completed) ES (Completed) BG (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004232-37 | Sponsor Protocol Number: D5134C00003 | Start Date*: 2017-12-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Strok... | |||||||||||||
Medical condition: Ischaemic stroke, transient ischaemic attack | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) HU (Completed) BG (Completed) FR (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) SK (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004220-23 | Sponsor Protocol Number: VIDEAT | Start Date*: 2008-09-04 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: EFFECT OF SUPPLEMENTATION WITH CHOLECALCIFEROL ON GLUCOSE AND LIPID METABOLISM, BLOOD PRESSURE, BONE MASS, QUALITY OF LIFE, CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH ISCHAEMIC HEART D... | |||||||||||||
Medical condition: ISCHAEMIC ARTERY DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002234-39 | Sponsor Protocol Number: BAY59-7939/15693 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose... | |||||||||||||
Medical condition: prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation scheduled for cardioversion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PT (Completed) ES (Completed) NL (Completed) DE (Completed) GR (Completed) BE (Completed) GB (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001757-21 | Sponsor Protocol Number: ESH-CHL-SHOT | Start Date*: 2013-05-21 | |||||||||||
Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO | |||||||||||||
Full Title: European Society of Hypertension and Chinese Hypertension League stroke in hypertension optimal treatment trial | |||||||||||||
Medical condition: Patients with arterial hypertension and previous stroke or transient ischemic attack | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.